HPV vaccine efficacy in preventing persistent cervical HPV infection: a systematic review and meta-analysis.

INTRODUCTION We performed a pooled analysis of randomised clinical trials (RCT) on HPV vaccine efficacy in preventing cervical persistent infection. METHODS We carried out a bibliographic search on electronic databases and we selected RCT to perform the meta-analyses. RESULTS We selected five studies. The first meta-analysis, including all studies, showed an important reduction of the risk of infection from HPV 16 in vaccinated cohort [RR 0.10 (95% CI: 0.07-0.15)]. The second and third meta-analyses, including only studies on bivalent and tetravalent vaccines, showed a RR of 0.13 (95% CI: 0.09-0.20) for HPV 16 infections and a RR of 0.22 (95% CI: 0.13-0.38) for HPV 18 ones. DISCUSSION HPV vaccine efficacy in preventing persistent infection is high but there is the need for further studies on the duration of immunization and long-term vaccine efficacy.

[1]  S. Franceschi,et al.  Prevalence of human papillomavirus infection in women in Turin, Italy. , 2005, European journal of cancer.

[2]  M. Lehtinen,et al.  Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. , 2007, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.

[3]  J M Garden,et al.  Papillomavirus in the vapor of carbon dioxide laser-treated verrucae. , 1988, JAMA.

[4]  Eduardo Lazcano-Ponce,et al.  Safety and Persistent Immunogenicity of a Quadrivalent Human Papillomavirus Types 6, 11, 16, 18 L1 Virus-Like Particle Vaccine in Preadolescents and Adolescents: A Randomized Controlled Trial , 2007, The Pediatric infectious disease journal.

[5]  D. Merlo,et al.  Prevalence of human papillomavirus cervical infection in an Italian asymptomatic population , 2005, BMC infectious diseases.

[6]  G. Nuovo,et al.  Human papillomavirus type 16 DNA in periungual squamous cell carcinomas. , 1989, JAMA.

[7]  J. Doorbar,et al.  Human Papillomaviruses , 2006, Methods in Molecular Medicine.

[8]  C. Wheeler,et al.  Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts , 1995, Journal of clinical microbiology.

[9]  G. Krogh,et al.  High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up , 2006, British Journal of Cancer.

[10]  J. Baseman,et al.  The epidemiology of human papillomavirus infections. , 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[11]  S. Franceschi,et al.  Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis , 2005, The Lancet.

[12]  J. Cuzick,et al.  Overview of the European and North American studies on HPV testing in primary cervical cancer screening , 2006, International journal of cancer.

[13]  A R Jadad,et al.  Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.

[14]  C. Wheeler,et al.  A controlled trial of a human papillomavirus type 16 vaccine. , 2002, The New England journal of medicine.

[15]  K. Ault Vaccines for the prevention of human papillomavirus and associated gynecologic diseases: a review. , 2006, Obstetrical & gynecological survey.

[16]  H. Kashima,et al.  A comparison of risk factors in juvenile‐onset and adult‐onset recurrent respiratory papillomatosis , 1992, The Laryngoscope.

[17]  C. Wheeler,et al.  Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomized, controlled trial , 2005 .

[18]  C. Wheeler,et al.  Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial , 2006, The Lancet.

[19]  Henry C Kitchener,et al.  Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial , 2007, The Lancet.

[20]  C. Wheeler,et al.  Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine. , 2004, Vaccine.

[21]  J. Walboomers,et al.  Human papillomavirus and cutaneous warts in meat handlers , 1993, Journal of clinical microbiology.

[22]  Cosette M Wheeler,et al.  Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. , 2005, The Lancet. Oncology.

[23]  Daron G Ferris,et al.  Efficacy of a bivalent L 1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women : a randomised controlled trial , 2005 .

[24]  J. Peto,et al.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.

[25]  C. Wheeler,et al.  Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia: A Randomized Controlled Trial , 2006, Obstetrics and gynecology.

[26]  C. Wheeler,et al.  Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. , 2006, Vaccine.

[27]  L. Markowitz,et al.  Genital human papillomavirus infection. , 2006, The New Zealand medical journal.

[28]  Daron G Ferris,et al.  Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial , 2004, The Lancet.

[29]  K. Holmes,et al.  Epidemiology of genital human papillomavirus infection. , 1988, Epidemiologic reviews.

[30]  A. Cicchetti,et al.  Health Technology Assessment and vaccine: new needs and opportunities? , 2007 .

[31]  M. Schiffman,et al.  Human Papillomavirus Epidemiology and Public Health , 2022 .